Effect of rTMS of the Cerebellum on Parkinson's Disease

Launched by JIANGSU PROVINCE NANJING BRAIN HOSPITAL · May 6, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment called low-frequency repetitive Transcranial Magnetic Stimulation (rTMS) aimed at helping people with Parkinson's disease. The researchers want to see if this non-invasive technique can improve symptoms for patients diagnosed with Parkinson's, a condition that affects movement and coordination.

To participate, individuals must be between 40 and 80 years old and have a confirmed diagnosis of Parkinson's disease. They should not have severe mental health issues or other significant neurological disorders. Participants will receive treatment while continuing their usual Parkinson's medications. The trial is currently open for recruitment, and those who join can expect to undergo rTMS therapy in a supportive environment. It's important for potential participants to be able to understand the study details and provide informed consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed with Parkinson's disease according to the clinical diagnostic criteria for Parkinson's disease (2015 edition) by the Movement Disorder Society (MDS)
• • 2. Citizens of the People's Republic of China of either sex, aged between 40 and 80 years.
• • 3. Able to give informed consent and follow the research plan.
• • 4. Hoehn-Yahr (H-Y) stage ≤ 3
• • 5. Patients received a Parkinson's stable medication before treatment (assessed via self report), which continued during treatment.
• Exclusion Criteria:
• • 1. History or diagnosis of severe psychiatric disorders, such as depression, anxiety disorders, schizophrenia spectrum disorders, and bipolar disorders.
• • 2. Subjects with a clinically defined neurological disorder (assessed via self report) including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, history of stroke, transient ischemic attack within two years, cerebral aneurysm, dementia, multiple sclerosis.
• • 3. Significant cognitive disorders (Mini-Mental State Exam (MMSE)\<24 points) or unable to complete the questionnaire independently.
• • 4. Intracranial implants, such as cochlear implants, aneurysms clips, shunts, stimulators, electrodes, cardiac pacemakers and vagus nerve stimulation devices.
• • 5. Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold (assess via self report).
• • 6. Showed significant discomfort after receiving the rTMS treatment.
• • 7. Participated in other clinical trials.
• • 8. Inability to read or understand Chinese.